[go: up one dir, main page]

MA41188B1 - Compositions d'insuline à action rapide - Google Patents

Compositions d'insuline à action rapide

Info

Publication number
MA41188B1
MA41188B1 MA41188A MA41188A MA41188B1 MA 41188 B1 MA41188 B1 MA 41188B1 MA 41188 A MA41188 A MA 41188A MA 41188 A MA41188 A MA 41188A MA 41188 B1 MA41188 B1 MA 41188B1
Authority
MA
Morocco
Prior art keywords
acting insulin
rapid acting
chloride
insulin compositions
insulin
Prior art date
Application number
MA41188A
Other languages
English (en)
Other versions
MA41188A (fr
Inventor
Michael Patrick Akers
Ranajoy Majumdar
Chi A Nguyen
Chad D Paavola
Virender Kumar Sarin
Nanette Elizabeth Schulte
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55066806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41188(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA41188A publication Critical patent/MA41188A/fr
Publication of MA41188B1 publication Critical patent/MA41188B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition d'insuline humaine ou d'un analogue de l'insuline qui comprend des concentrations spécifiques de citrate, de chlorure, dans certains cas comprenant l'ajout de chlorure de sodium, de zinc et, facultativement, de chlorure de magnésium et/ou de surfactant, et qui a une action pharmacocinétique et/ou pharmacodynamique plus rapide que les formulations commerciales de produits analogues de l'insuline existants.
MA41188A 2014-12-16 2015-12-09 Compositions d'insuline à action rapide MA41188B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092407P 2014-12-16 2014-12-16
PCT/US2015/064744 WO2016100042A1 (fr) 2014-12-16 2015-12-09 Compositions d'insuline à action rapide

Publications (2)

Publication Number Publication Date
MA41188A MA41188A (fr) 2017-10-24
MA41188B1 true MA41188B1 (fr) 2022-08-31

Family

ID=55066806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41188A MA41188B1 (fr) 2014-12-16 2015-12-09 Compositions d'insuline à action rapide

Country Status (18)

Country Link
US (4) US9993555B2 (fr)
EP (2) EP3233108B1 (fr)
JP (5) JP6328855B2 (fr)
AR (1) AR102869A1 (fr)
CY (1) CY1125275T1 (fr)
DK (1) DK3233108T3 (fr)
ES (1) ES2911207T3 (fr)
HR (1) HRP20220692T1 (fr)
HU (1) HUE058764T2 (fr)
LT (1) LT3233108T (fr)
MA (1) MA41188B1 (fr)
MD (1) MD3233108T2 (fr)
PL (1) PL3233108T3 (fr)
PT (1) PT3233108T (fr)
RS (1) RS63174B1 (fr)
SI (1) SI3233108T1 (fr)
TW (1) TW201630622A (fr)
WO (1) WO2016100042A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691759B2 (en) 2008-03-18 2014-04-08 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
MX360107B (es) 2012-11-13 2018-10-23 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido.
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
KR102482664B1 (ko) * 2016-09-29 2022-12-29 아레콜 리미티드 신규한 제제
PE20210857A1 (es) 2016-12-16 2021-05-18 Novo Nordisk As Composiciones farmaceuticas que contienen insulina
US20180236080A1 (en) * 2017-02-22 2018-08-23 Adocia Fast-acting insulin composition comprising a citric acid salt
MX2019011603A (es) * 2017-03-26 2021-08-16 Robyn Vivi Stafford Metodo de tratamiento de las condiciones de la piel de los parpados.
MA50496A (fr) * 2017-06-01 2020-09-09 Lilly Co Eli Compositions d'insuline à action rapide
WO2019193353A1 (fr) 2018-04-04 2019-10-10 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
EP3773472A1 (fr) 2018-04-04 2021-02-17 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
IL277720B2 (en) * 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2020186154A1 (fr) * 2019-03-14 2020-09-17 The Regents Of The University Of California Procédés et compositions pour la prise en charge de la santé rénale
US10639328B1 (en) * 2019-03-27 2020-05-05 College Of William & Mary Compositions and methods for reducing hyperglycemia and treating diabetes
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
KR20220066317A (ko) * 2019-09-17 2022-05-24 카스 파마슈티컬스, 인크. 피하 주사가능 인슐린 제제 및 투여 방법
EP4049032A1 (fr) 2019-10-25 2022-08-31 Cercacor Laboratories, Inc. Composés indicateurs, dispositifs comprenant des composés indicateurs, et leurs procédés de fabrication et d'utilisation
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK116527B (da) 1967-03-01 1970-01-19 Nordisk Insulinlab Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
EP0018609B1 (fr) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NO162160C (no) 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
NZ223630A (en) 1987-02-25 1989-11-28 Novo Industri As Insulin derivative and pharmaceutical compositions
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
AU1870099A (en) 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
WO2000043034A2 (fr) 1999-01-26 2000-07-27 Eli Lilly And Company Formulations d'analogues d'insuline acyles hexameres monodisperses
AU779798C (en) 1999-11-15 2005-11-17 Hanamaraddi T. Gangal Dextrose and insulin fluid formulation for intravenous infusion
JP4147234B2 (ja) 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ATE525083T1 (de) 2003-11-13 2011-10-15 Novo Nordisk As Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008013955A2 (fr) 2006-07-27 2008-01-31 Nektar Therapeutics Formulations à libération prolongée pour administration pulmonaire
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
EP2036539A1 (fr) 2007-09-11 2009-03-18 Novo Nordisk A/S Formulations stables d'amyline et ses analogues
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
EP2590667A4 (fr) 2010-07-07 2013-11-27 Biodel Inc Compositions et procédés pour la modulation de la pharmacocinétique et de la pharmacodynamie de l'insuline
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
JP2014518216A (ja) 2011-06-17 2014-07-28 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の安定な製剤
EP2720713A2 (fr) 2011-06-17 2014-04-23 Halozyme, Inc. Procédés de perfusion d'insuline sous-cutanée continue utilisant une enzyme de dégradation de l'hyaluronane
US20130231281A1 (en) * 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
LT3130347T (lt) 2011-12-30 2019-10-25 Halozyme Inc Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
WO2013177565A1 (fr) 2012-05-25 2013-11-28 Amylin Pharmaceuticals, Llc Compositions d'insuline/pramlintide et leurs procédés de fabrication et d'utilisation
MX360107B (es) * 2012-11-13 2018-10-23 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido.
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
CA2936563A1 (fr) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Formulations d'insuline a action rapide et systemes d'administration pharmaceutique
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
US20220072105A1 (en) 2022-03-10
LT3233108T (lt) 2022-05-10
JP2023011641A (ja) 2023-01-24
US11872266B2 (en) 2024-01-16
JP2018500314A (ja) 2018-01-11
JP7093669B2 (ja) 2022-06-30
MA41188A (fr) 2017-10-24
WO2016100042A1 (fr) 2016-06-23
RS63174B1 (sr) 2022-05-31
US11123406B2 (en) 2021-09-21
MD3233108T2 (ro) 2022-09-30
AR102869A1 (es) 2017-03-29
US9993555B2 (en) 2018-06-12
SI3233108T1 (sl) 2022-05-31
EP3233108B1 (fr) 2022-03-30
JP6328855B2 (ja) 2018-05-23
US20160166695A1 (en) 2016-06-16
ES2911207T3 (es) 2022-05-18
JP7159277B2 (ja) 2022-10-24
CY1125275T1 (el) 2024-12-13
JP2021073187A (ja) 2021-05-13
HRP20220692T1 (hr) 2022-07-08
HUE058764T2 (hu) 2022-09-28
US20240238382A1 (en) 2024-07-18
JP2018138578A (ja) 2018-09-06
PT3233108T (pt) 2022-05-05
US20190231851A1 (en) 2019-08-01
PL3233108T3 (pl) 2022-06-20
EP4108253A1 (fr) 2022-12-28
TW201630622A (zh) 2016-09-01
EP3233108A1 (fr) 2017-10-25
JP2025032126A (ja) 2025-03-11
DK3233108T3 (da) 2022-04-11

Similar Documents

Publication Publication Date Title
MA41188B1 (fr) Compositions d'insuline à action rapide
MA42701B1 (fr) Compositions d'insuline à action rapide
MA39441A1 (fr) Composition d'insuline a action rapide
PH12017502359B1 (en) Glucagon and glp-1 co-agonist compounds
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
MA40466A (fr) Utilisation d'agoniste double de récepteur de glp-1/glucagon à action prolongée permettant le traitement de stéatose hépatique non-alcoolique
CL2014001060A1 (es) Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades.
MX2016008977A (es) Formulaciones farmaceuticas de insulina aspart estabilizadas.
MX2017004662A (es) Composiciones y metodos para mejorar la movilidad o actividad o tratar la fragilidad.
MA38646A1 (fr) Formulation a liberation modifiee pour traiter, par ex. La maladie de parkinson et la dyskinesie induite par l-dopa.
MA39133A1 (fr) Composition pour la lutte contre la poussière
MY190102A (en) Tolerogenic dna vaccine
EP3835311C0 (fr) Fragment de nkx3.2 et composition pharmaceutique le comprenant en tant que principe actif
MX2017006747A (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.
WO2019035602A3 (fr) Diagnostic du cancer de l'estomac à l'aide de la protéine gkn1 du sang
AR099750A1 (es) COMPOSICIONES PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE PATOLOGÍAS RELACIONADAS CON LA a-GLUCOSIDASA